Dianthus Therapeutics (DNTH)
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its l...
- Open
- 108.030
- High
- 110.240
- Low
- 105.945
- Prev. Close
- 109.130
- Volume
- 1.03M
- Turnover
- 110.81M
- Avg Price
- 107.178
- Bid/Ask Ratio
- 0.00%
- Amplitude
- 3.94%
- 52wk High
- 117.875
- Volume Ratio
- 1.30
- Turnover Ratio
- 1.85%
Dianthus Therapeutics Analyst Rating
View moreForecast & Rating
Sep 4, 2026Price forecast
$141.2131.93%
Forecast & RatingStrong buy
15analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Sep 3 at 08:31 PM
Dianthus EVP, Head of R&D Simrat Randhawa sells USD 2.45 million in common shares
- StockTitan · Sep 2 at 01:00 PM
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | DNTH Stock News
- PUBT · Sep 1 at 12:06 PM
Dianthus Therapeutics CEO to join Citi Biopharma Back to School fireside chat
- Market Beat · Aug 20 at 08:00 AM
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week High - Still a Buy?
- Market Beat · Aug 19 at 11:22 PM
Simon Read Sells 2,778 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock
- PUBT · Aug 19 at 10:03 PM
Dianthus Therapeutics director Simon Read disposes of common shares worth $326,148.9
